Martin Borch Jensen
@martinbjensen.bsky.social
Aging, Systems Biology, Gene Therapy. CSO @GordianBio, doing mosaic therapeutic screens in vivo.
Also @NornGroup/Impetus Grants. Previously K99 Fellow @Buck Institute.
Also @NornGroup/Impetus Grants. Previously K99 Fellow @Buck Institute.
San Francisco license plates
South San Francisco license plates
South San Francisco license plates
March 28, 2025 at 4:29 PM
San Francisco license plates
South San Francisco license plates
South San Francisco license plates
TL;DR in this thread:
Safety is a real concern, highlighted again this week. From ~7000 patients dosed, we've learned that doses above 5E13 have serious risks, but lower doses have fewer serious adverse events than small molecules.
Safety is a real concern, highlighted again this week. From ~7000 patients dosed, we've learned that doses above 5E13 have serious risks, but lower doses have fewer serious adverse events than small molecules.
March 20, 2025 at 2:29 PM
TL;DR in this thread:
Safety is a real concern, highlighted again this week. From ~7000 patients dosed, we've learned that doses above 5E13 have serious risks, but lower doses have fewer serious adverse events than small molecules.
Safety is a real concern, highlighted again this week. From ~7000 patients dosed, we've learned that doses above 5E13 have serious risks, but lower doses have fewer serious adverse events than small molecules.
Kristien emphasizing the casual nature of our Apprenticeship program's lunch and learns. This session was on the MrBeast production memo's examples of showing ownership of outcomes, and the cumulative impact of obsessing over improvement.
November 21, 2024 at 5:00 PM
Kristien emphasizing the casual nature of our Apprenticeship program's lunch and learns. This session was on the MrBeast production memo's examples of showing ownership of outcomes, and the cumulative impact of obsessing over improvement.
qPCR
Very happy we tested Analytik Jena qTOWER (redoing a prior run). Smaller footprint than QuantStudio/Lightcycler, cheaper, longer warranty, has everything we want in a qPCR (e.g. save data after each cycle). Plus it looks like it might evolve AGI and start running the lab.
2024: No regrets.
Very happy we tested Analytik Jena qTOWER (redoing a prior run). Smaller footprint than QuantStudio/Lightcycler, cheaper, longer warranty, has everything we want in a qPCR (e.g. save data after each cycle). Plus it looks like it might evolve AGI and start running the lab.
2024: No regrets.
November 11, 2024 at 7:50 PM
qPCR
Very happy we tested Analytik Jena qTOWER (redoing a prior run). Smaller footprint than QuantStudio/Lightcycler, cheaper, longer warranty, has everything we want in a qPCR (e.g. save data after each cycle). Plus it looks like it might evolve AGI and start running the lab.
2024: No regrets.
Very happy we tested Analytik Jena qTOWER (redoing a prior run). Smaller footprint than QuantStudio/Lightcycler, cheaper, longer warranty, has everything we want in a qPCR (e.g. save data after each cycle). Plus it looks like it might evolve AGI and start running the lab.
2024: No regrets.
(Inspired by a conversation today)
If you're excited to help Biotech using AI, keep this chart in mind - the best way to improve cost+time per drug is to reduce risk of trial failure, not to use AI to make new molecules cheaper and faster.
If you're excited to help Biotech using AI, keep this chart in mind - the best way to improve cost+time per drug is to reduce risk of trial failure, not to use AI to make new molecules cheaper and faster.
November 30, 2023 at 12:33 AM
(Inspired by a conversation today)
If you're excited to help Biotech using AI, keep this chart in mind - the best way to improve cost+time per drug is to reduce risk of trial failure, not to use AI to make new molecules cheaper and faster.
If you're excited to help Biotech using AI, keep this chart in mind - the best way to improve cost+time per drug is to reduce risk of trial failure, not to use AI to make new molecules cheaper and faster.